Debourdeau Eloi, Builles Nicolas, Couderc Guilhem, Boulhic Jimmy, Chamard Chloe, Villain Max, Babeau Fanny, Daien Vincent
Department of Ophthalmology, Gui de Chauliac Hospital, 80 avenue Augustin Fliche, F-34000, Montpellier, France.
Montpellier University, F-34000, Montpellier, France.
Graefes Arch Clin Exp Ophthalmol. 2022 Nov;260(11):3627-3638. doi: 10.1007/s00417-022-05691-w. Epub 2022 May 12.
To assess risk factors of rejection after penetrating keratoplasty (PKP).
This retrospective monocentric study assessed risk factors for rejection in patients who underwent PKP at Montpellier University Hospital between June 2005 and September 2018. Graft and donor data were obtained from our tissue bank in Montpellier. Clinical data of recipients were recorded from medical files. Survival was estimated by the Kaplan-Meir method. Potential risk factors of rejection were assessed by multivariate Cox proportional hazards analysis, estimating hazard ratios (HR) and 95% confidence intervals (CI).
Among the 316 consecutive patients (59% male, mean SD] age 52 [17]), 360 eyes underwent PKP. Indications for PKP were bullous keratopathy (27%), infectious keratitis (20%), and keratoconus (15%). The median follow-up was 44 months (IQR 22-73). The overall graft survival and irreversible rejection rate at 5 years were 70% and 29%, respectively. Factors associated with risk of rejection were prior indication for graft rejection (SHR [CI 95%] = 7.8 [2.6-23.1]), trauma (SHR [CI 95%] = 3.6 [1.1-11.7]), and infectious keratitis (SHR [CI 95%] = 2.7 [1.2-11.1]), history of corneal neovascularization (SHR [CI 95%] = 2.1 [1.2-3.8]), hypertonia (SHR [CI 95%] = 2.8 [1.8-4.3]), and mixed sex matching (SHR [CI 95%] = 2.0 [1.01-4.0]).
The significant risk factors of graft rejection after PKP found in this study agree with those from major international cohorts: prior indication for graft rejection, history of neovascularization and high intraocular pressure. Sex matching donor-recipient is a most recent parameter in the literature confirmed by the present analysis.
ClinicalTrials.gov Identifier: NCT04791696.
评估穿透性角膜移植术(PKP)后排斥反应的危险因素。
这项回顾性单中心研究评估了2005年6月至2018年9月在蒙彼利埃大学医院接受PKP的患者发生排斥反应的危险因素。移植和供体数据来自蒙彼利埃的组织库。从病历中记录受者的临床数据。采用Kaplan-Meir法估计生存率。通过多变量Cox比例风险分析评估排斥反应的潜在危险因素,估计风险比(HR)和95%置信区间(CI)。
在316例连续患者(59%为男性,平均标准差年龄52岁[17岁])中,360只眼接受了PKP。PKP的适应证为大泡性角膜病变(27%)、感染性角膜炎(20%)和圆锥角膜(15%)。中位随访时间为44个月(四分位间距22 - 73个月)。5年时的总体移植存活率和不可逆排斥率分别为70%和29%。与排斥风险相关的因素包括既往移植排斥指征(SHR[CI 95%]=7.8[2.6 - 23.1])、外伤(SHR[CI 95%]=3.6[1.1 - 11.7])、感染性角膜炎(SHR[CI 95%]=2.7[1.2 - 11.1])、角膜新生血管病史(SHR[CI 95%]=2.1[1.2 - 3.8])、高眼压(SHR[CI 95%]=2.8[1.8 - 4.3])以及性别混合匹配(SHR[CI 95%]=2.0[1.01 - 4.0])。
本研究中发现的PKP后移植排斥的重要危险因素与主要国际队列研究的结果一致:既往移植排斥指征、新生血管病史和高眼压。供受体性别匹配是本分析证实的文献中最新的一个参数。
ClinicalTrials.gov标识符:NCT04791696。